New Methods in Computational Drug Discovery – A GPCR Case Study

Hans Henrik co-founded Kvantify with a steadfast vision: to tackle the world’s toughest computational challenges, creating significant value for businesses and society alike. He has an extensive background as a senior executive in the software and telecommunications industries, complemented by a Ph.D. in Nuclear Physics from Aarhus University. His career includes over a decade in management roles and five years at McKinsey, where he specialized in business and technology strategies.
As an active partner, Hans Henrik is at the forefront of driving Kvantify’s mission to develop pioneering solutions that redefine industry standards, bridging technology with practical applications in life sciences and other sectors. His leadership is instrumental in steering the company towards innovative breakthroughs that have a profound impact on the industry.

Mikael Hvidtfeldt Christensen is a seasoned expert in drug discovery and bioinformatics, with over 20 years of experience in developing commercial software applications. In 2005, he co-founded Molegro, a company specializing in in-silico drug discovery, with a focus on molecular docking and QSAR modeling.
After Molegro was acquired by CLC bio (now QIAGEN Aarhus) in 2012, Mikael continued his work in structure-based drug discovery, bioinformatics, and systems biology. In 2023, Mikael joined Kvantify as a computational biology specialist and technical product manager. He holds an MSc in Physics from Aarhus University.

Morten Allesø currently holds the position as Chief Scientific Officer at Tetra Pharm Technologies; a Danish-based biotech company founded in 2018. TPT performs research and development of compounds targeting the Endocannabinoid System (ECS) to treat neuropathic pain and mental health disorders. Morten earned his Master of Pharmaceutical Science at University of Copenhagen (UCPH) in 2006 and his PhD in 2009 from Department of Pharmacy (also UCPH). Throughout his more than 15-year industrial career he has held several positions within drug delivery / pharmaceutical development and manufacturing, including H. Lundbeck and as a consultant at Novo Nordisk Engineering. He has made several contributions to the academic field with 15+ peer-reviewed scientific publications.

David Gloriam is a Professor in Computational Receptor Biology at the University of Copenhagen. He heads the G protein-coupled receptor (GPCR) database, GPCRdb and the related online research resources GproteinDb, ArrestinDb and Biased Signaling Atlas. He is a corresponding member of the nomenclature committee for drugs and targets of the International Union of Pharmacology.

Gloriam got his PhD from Uppsala University identifying novel human GPCRs. He later discovered physiological hormones of such undercharacterized ‘orphan’ receptors. He was a postdoc at EMBL-EBI and GlaxoSmithKline. He has been awarded an ERC Starting Grant, Lundbeck Foundation Fellowship, Novo Nordisk Foundation Ascending Investigator and the Royal Danish Academy of Sciences and Letters special research prize within big data. Gloriam has the role of Scientific Expert at Kvantify.